Physicians prescribe the drug Actos to regulate blood sugar levels as a treatment for Type 2 diabetes. The drug made billions for its manufacturer, Takeda Pharmaceuticals, and was the company’s blockbuster drug. Unfortunately, long-term use of Actos is linked to a number of serious health complications, including bladder cancer that led to lawsuits against Takeda.
Approved by the U.S. Food and Drug Administration (FDA) in 1999, the type 2 diabetes drug Actos (pioglitazone) was one of Takeda Pharmaceuticals’ best-selling drugs. With diet and exercise, it helps control blood sugar. But, it is also a controversial drug that is linked to a number of serious side effects, including congestive heart failure, kidney disease and bladder cancer.
Eli Lilly partnered with Takeda to market the drug, and it became one of the most successful diabetes medications of all time. Before the manufacturer lost the patent on Actos in 2011, its U.S. sales were $3.58 billion in 2010. The drug’s sales made up 27 percent of the manufacturer’s revenue.
But, it is a possible side effect unique to Actos that now raises concern: bladder cancer. In August 2011, the FDA required that Takeda update the drug’s Warnings and Precautions section of the label to include a warning that use of the drug for over a year may be associated with an increased risk of bladder cancer.
BMJ published the latest study on pioglitazone in May 2012. This study revealed that people who take Actos for an extended period have an 83 percent higher risk of developing bladder cancer.
Before 2012, a few studies – including Takeda’s own preclinical trials – already linked the drug to bladder problems. In animal studies, male rats suffered from bladder tumors after receiving the drug.
According to the FDA, in two additional three-year studies (a liver safety study and the PROactive study) researchers noted a higher incidence of bladder cancer in patients who took Actos versus those who took other drugs. As a result of these studies, the FDA required that Takeda undertake a 10-year study of the drug’s link to bladder cancer.
The FDA will review the data once it is available to further evaluate the drug’s safety.
|Bladder Cancer Symptoms|
|Bloody Urine||Increased urge to urinate|
|Pain when urinating||Unusual back pain|
Actos can have other side effects for users beyond bladder cancer and congestive heart failure. Other potentially dangerous ones are chronic kidney disease, lactic acidosis and bone fractures.
Researchers from Taiwan’s Kaohsiung Medical University published a study in PLoS One that found the Type 2 diabetes drug increased the risk of chronic kidney disease. The study followed 35,000 people with diabetes from 2005 to 2009. People who took Actos were four times more likely to develop kidney disease than those who did not.
|Lactic acidosis is a potentially fatal condition with symptoms of:|
|Any diabetes issues (macular edema or diabetic ketoacidosis)||Fever|
|Heart problems or severe heart failure||Trauma|
|Type 1 diabetes||Active bladder cancer or a history of bladder cancer|
|Liver disease||Pregnancy or plans to become pregnant|
Among patients who took Actos, there were reports of some fatal and nonfatal cases of liver failure. According to the drug’s warnings and precautions insert, there is no way to definitively prove that it does not cause liver issues.
Still, doctors should test each patient’s liver prior to prescribing the drug and monitor each patient for signs of liver damage, including:
Thousands of people who took the drug filed lawsuits against Takeda Pharmaceuticals and Elli Lilly after doctors diagnosed them with bladder cancer.
In the first federal trial, a Louisiana jury awarded $9 billion in punitive damages and $1.5 million in compensatory damages to Terrence Allen, a former shopkeeper from New York who said Actos caused his bladder cancer. Allen’s lawyers argued that the company “was more concerned with making money” than watching out for patient safety.
Takeda in April 2015 agreed to settle thousands of Actos bladder cancer claims for at least $2.37 billion in one of the largest pharmaceutical settlements in U.S. mass torts history. The record Actos settlement covers about 9,000 cases and means about $275,000 for those who sign into the settlement, which outlines guidelines to qualify for compensation. The cost of the agreement could rise to $2.7 billion.